Dormant
RMAX · Re/Max Holdings, Inc.
Last analysed ·
Resolved Graded and closed 2026-07-31 at medium conviction — the published kill line fired. Coverage continued after the close; the read below is dated 2026-09-20 and is not part of the scored record.
Current thesis
Merger arb that finally got a date. DOJ granted HSR early termination 2026-07-13 and both special meetings are set for 2026-08-14, removing the regulatory leg. RMAX $11.10 vs ~$11.86 blended (5.150 REAX at $2.21 plus the prorated $13.80 cash pool) — roughly 7% over six weeks. The residual risk is unhedged REAX beta, not deal failure.
Kill line
A weekly close below $9.50 breaks the post-HSR arb floor and implies REAX back under $1.80 or fresh doubt on the vote. Secondary: either shareholder meeting on 2026-08-14 failing to approve, or the meetings being adjourned without a new date.
Pick status
Invalidated resolved published kill line fired How this is scored →Latest analysis and events for RMAX —
As of 20 September 2026, the latest FrontierPicks analysis for Re/Max Holdings, Inc. (RMAX): Merger arb that finally got a date. DOJ granted HSR early termination 2026-07-13 and both special meetings are set for 2026-08-14, removing the regulatory leg. RMAX $11.10 vs ~$11.86 blended (5.150 REAX at $2.21 plus the prorated $13.80 cash pool) — roughly 7% over six weeks. The residual risk is unhedged REAX beta, not deal failure.
Kill line: A weekly close below $9.50 breaks the post-HSR arb floor and implies REAX back under $1.80 or fresh doubt on the vote. Secondary: either shareholder meeting on 2026-08-14 failing to approve, or the meetings being adjourned without a new date.
Current Thesis
RE/MAX Holdings’ merger thesis resolved with completion on 2026-08-24; any subsequent operating recovery belongs to successor REAX, while RMAX has no continuing price-discovery mechanism. The companies’ completion announcement states that RMAX ceased trading that day and the combined company began trading as REAX on 2026-08-25. Completion announcement
The narrative is dead as a standalone RMAX catalyst — the transaction completed on 2026-08-24. That classification describes the security’s lifecycle, not a failed acquisition. The material clarification is that the closing filing reports final consideration, replacing the preliminary election figures with completed transaction terms. Closing filing
Bullish and bearish views on Re/Max Holdings, Inc.
The model's bull view on Re/Max Holdings, Inc. (RMAX), in brief: Completion removed transaction uncertainty. The bear view: Standalone earnings missed estimates. Benzinga’s 2026-08-06 results report records second-quarter adjusted earnings per share of $0.32 against a $0.39 estimate, and revenue of $68.510 million against $72.700 million. Those reported misses leave operating improvement unproven at… Both cases follow in full.
Bull Case
- Completion removed transaction uncertainty. The 2026-08-24 announcement confirms the business combination and identifies REAX as the successor listing beginning 2026-08-25. This is evidence of a resolved catalyst, not an outstanding merger spread. Completion announcement
- Combined scale is documented. The successor’s investor-relations page, reviewed on 2026-09-20, presents combined fiscal 2025 revenue of $2.3 billion. Its footnote explicitly says these combined results are not regulatory pro forma financial statements; they establish historical scale without demonstrating post-merger performance. Investor relations
Bear Case
- Standalone earnings missed estimates. Benzinga’s 2026-08-06 results report records second-quarter adjusted earnings per share of $0.32 against a $0.39 estimate, and revenue of $68.510 million against $72.700 million. Those reported misses leave operating improvement unproven at completion.
- Cash elections retained stock exposure. Final terms filed on 2026-08-24 gave cash electors approximately $4.33 in cash plus approximately 0.3535 successor shares per former Class A share; stock electors received 0.5150 successor shares. The consideration therefore included a continuing equity component. Closing filing
Setup & Price Structure
The supplied adjusted daily series ends at $12.36 on 2026-08-24, with a three-month price increase of 30.7% and a 14-day relative strength index (RSI) of 69.7. These are historical observations from the final trading session. They cannot establish a current breakout, moving-average relationship or renewed participation after trading ceased.
Benzinga included RMAX in its high-RSI real-estate coverage on 2026-08-18. That is a dated attention observable; one article and a terminal momentum reading are too small a sample to support a crowding claim. No current moving-average measurement or positioning series is supplied.
Catalyst Calendar (next 30 days)
For 2026-09-20 through 2026-10-20, no confirmed RMAX catalyst was identified in the reviewed company materials. The successor’s investor-relations page supplies no verified upcoming earnings date for this window. Investor relations
The 2026-08-24 filing requested removal from listing and described an intended subsequent termination of registration. It did not establish a September completion date for that administrative process, so no dated deregistration catalyst is asserted. Closing filing
What Would Change Our Mind
Restoration of a separately listed RMAX security, documented by an exchange notice and an issuer filing, would overturn the conclusion that its standalone market narrative has ended. The controlling evidence remains the 2026-08-24 completion announcement. Completion announcement
A weekly close below $12.36 would breach the final 2026-08-24 reference close, but that condition is inactive because RMAX ceased trading. There is no defensible live price-based forecast for the cancelled line, and a successor-company price threshold would test a different security.
Correlation Notes
The fixed stock consideration documented on 2026-08-24 explains the transaction’s economic link to REAX. It does not establish a measured return correlation with housing shares, mortgage rates or a broader property-technology group. Completion announcement
This remains a single-name completed transaction. The supplied market observations end on 2026-08-24 and contain no paired return series sufficient to support a group-correlation claim.
Notes
- RMAX ceased trading on 2026-08-24 after merger completion. The successor began trading as REAX on 2026-08-25; the two symbols do not represent a continuous standalone RE/MAX equity listing.
Related · shared themes
APGE
Apogee Therapeutics, Inc.
Apogee Therapeutics’ $135.11-per-share cash-acquisition thesis resolved with AbbVie’s completion on 2026-09-03. The 2026-09-14 Form 15 advances administrative closure, leaving no unresolved APGE acquisition catalyst.
ATAI
AtaiBeckley Inc.
AtaiBeckley's Lilly acquisition thesis resolved with completion on 2026-09-11, ending the pending-merger case. Remaining contingent payments depend on disclosed clinical and regulatory milestones; Nasdaq suspended ATAI effective 2026-09-14.
DSGR
Distribution Solutions Group, Inc.
Distribution Solutions Group’s $35.00 cash acquisition remains a completion thesis, with the minority vote and closing settling the case. HSR clearance occurred on 2026-08-20; a daily close below $33.50 invalidates the price thesis.
ATKR
Atkore Inc.
Atkore's $95.00 cash-merger thesis now turns on the October 7 shareholder vote and remaining approvals after September 14 US antitrust clearance. Completion before a weekly close below $88 constitutes success; termination negates the case.